Drug Trial Radar · NCT05457257
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Jul 29, 2022
Primary completion
Oct 22, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; Foundation Medicine; Myriad Genetics, Inc.
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
olaparibDrug
300 mg (2x 150 mg tablets) twice daily
enzalutamideDrug
160 mg (4 x 40 mg capsules) once daily
abiraterone acetateDrug
1,000 mg (4 x 250 mg tablets) once daily
PrednisoneDrug
5mg(5mg x 1 tablet) twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)Time frame: Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Bengbu, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Jiaxing, China
Research Site
Jinan, China
Research Site
Jinan, China
Research Site
Jining, China
Research Site
Kunming, China
Research Site
Lanzhou, China
Research Site
Linyi, China
Research Site
Nanchang, China
Research Site
Nantong, China
Research Site
Ningbo, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Suzhou, China
Research Site
Taiyuan, China
Research Site
Tianjin, China
Research Site
Wanzhou, China
Research Site
Wuhan, China
Research Site
Wuxi, China
Research Site
Wuxi, China
Research Site
Xi'an, China
Research Site
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.